Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Interest & Investment Income: 2014-2024

Historic Interest & Investment Income for Ultragenyx Pharmaceutical (RARE) over the last 11 years, with Dec 2024 value amounting to $36.5 million.

  • Ultragenyx Pharmaceutical's Interest & Investment Income fell 45.36% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.0 million, marking a year-over-year decrease of 21.04%. This contributed to the annual value of $36.5 million for FY2024, which is 36.79% up from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported Interest & Investment Income of $36.5 million as of FY2024, which was up 36.79% from $26.7 million recorded in FY2023.
  • Ultragenyx Pharmaceutical's 5-year Interest & Investment Income high stood at $36.5 million for FY2024, and its period low was $1.9 million during FY2021.
  • In the last 3 years, Ultragenyx Pharmaceutical's Interest & Investment Income had a median value of $26.7 million in 2023 and averaged $24.8 million.
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Interest & Investment Income plummeted by 72.61% in 2021 and then soared by 474.38% in 2022.
  • Ultragenyx Pharmaceutical's Interest & Investment Income (Yearly) stood at $7.0 million in 2020, then tumbled by 72.61% to $1.9 million in 2021, then skyrocketed by 474.38% to $11.1 million in 2022, then spiked by 141.00% to $26.7 million in 2023, then spiked by 36.79% to $36.5 million in 2024.